Thomas Smith
Stock Analyst at Leerink Partners
(2.55)
# 2,630
Out of 5,182 analysts
59
Total ratings
35.59%
Success rate
20.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $49 → $106 | $71.90 | +47.43% | 1 | Apr 13, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $11.32 | +218.02% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $5.13 | +133.92% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $24.75 | +29.29% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $25.00 | +68.00% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $2.04 | -50.98% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $5.47 | +64.53% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $4.41 | +58.73% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.07 | +451.63% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $8.12 | +220.20% | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $111.90 | -82.13% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $783.74 | -44.50% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $68.85 | -47.71% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.45 | +185.71% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $28.62 | -26.62% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.50 | +233.33% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $14.27 | -57.95% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.63 | +128.14% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $90 → $50 | $9.98 | +401.00% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $16.85 | +0.89% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $33.66 | +90.14% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.35 | +303.46% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.46 | +651.45% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $32.99 | -63.62% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $11.01 | +626.61% | 2 | Dec 8, 2020 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Outperform
Price Target: $49 → $106
Current: $71.90
Upside: +47.43%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $11.32
Upside: +218.02%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $5.13
Upside: +133.92%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $24.75
Upside: +29.29%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $25.00
Upside: +68.00%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $2.04
Upside: -50.98%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $5.47
Upside: +64.53%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $4.41
Upside: +58.73%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.07
Upside: +451.63%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $8.12
Upside: +220.20%
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $111.90
Upside: -82.13%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $783.74
Upside: -44.50%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $68.85
Upside: -47.71%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.45
Upside: +185.71%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $28.62
Upside: -26.62%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $13.50
Upside: +233.33%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $14.27
Upside: -57.95%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.63
Upside: +128.14%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $90 → $50
Current: $9.98
Upside: +401.00%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $16.85
Upside: +0.89%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $33.66
Upside: +90.14%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.35
Upside: +303.46%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.46
Upside: +651.45%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $32.99
Upside: -63.62%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $11.01
Upside: +626.61%